Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | MMP1 | P03956 | 7/20 | 0.50 |
| ▸ | MMP9 | P14780 | 7/20 | 0.50 |
| ▸ | MMP13 | P45452 | 7/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7504704 | 0.94 | HRH3 (0.56) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7509731 | 0.90 | MMP13 (0.47) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7621990 | 0.88 | MMP13 (0.57) | HRH3MMP1MMP9MMP13ADAM17 | |
| SCHEMBL7570327 | 0.85 | MMP1 (0.53) | HRH3MMP1MMP9MMP13ADAM17 | |
| SCHEMBL7552262 | 0.85 | ALDH1A1 (0.46) | MMP1MMP9MMP13ADAM17KDM4E | |
| SCHEMBL7559733 | 0.85 | ALDH1A1 (0.46) | MMP1MMP9MMP13ADAM17KDM4E | |
| SCHEMBL7515093 | 0.84 | KCNH2 (0.46) | HRH3KCNH2KDM4EALDH1A1 | |
| SCHEMBL6934597 | 0.84 | ADAM17 (0.50) | MMP1MMP9MMP13ADAM17ALDH1A1 | |
| Hydroxyamine SCHEMBL7661687 | 0.84 | MMP1 (0.51) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7505846 | 0.83 | ALDH1A1 (0.49) | HRH3MMP1MMP13KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | HRH3 1187/4885KCNH2 3171/4885MMP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.